세계의 아미포스틴 : 시장 점유율과 순위, 전체 판매량 및 수요 예측(2025-2031년)

The global market for Amifostine was estimated to be worth US$ 52.1 million in 2024 and is forecast to a readjusted size of US$ 60.1 million by 2031 with a CAGR of 2.1% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Amifostine cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Amifostine (Ethiofos) is a cytoprotective adjuvant used in cancer chemotherapy and radiotherapy involving DNA-binding chemotherapeutic agents. It is marketed by Clinigen under the trade name Ethyol. In 2024, global Amifostine production reached approximately 4.68 M unit, with an average global market price of around US$ 22 per unit.

The amifostine market is primarily shaped by its role as a cytoprotective agent used alongside chemotherapy and radiotherapy to reduce toxic side effects such as xerostomia and myelosuppression. Its clinical application is most notable in cancer care, particularly for head and neck cancers, though off-label exploration in other areas has also contributed to steady demand. The growing incidence of cancer worldwide, coupled with the rising adoption of supportive care therapies, supports market expansion. Additionally, increasing awareness of treatment-related quality-of-life issues and hospital protocols emphasizing patient safety have sustained the relevance of amifostine in oncology.

At the same time, the market faces headwinds from high treatment costs, limited availability in some regions, and the emergence of alternative protective agents or treatment regimens with fewer side effects. Patent expiries and the entry of generics have led to greater price competition, particularly in emerging markets where affordability drives uptake. Opportunities lie in expanding access through generics, advancing formulations to reduce adverse reactions such as hypotension and nausea, and integrating amifostine into broader supportive oncology care strategies. Overall, while niche compared to mainstream oncology drugs, the amifostine market remains stable, supported by its unique protective benefits in cancer treatment.

This report aims to provide a comprehensive presentation of the global market for Amifostine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Amifostine by region & country, by Type, and by Application.

The Amifostine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Amifostine.

Market Segmentation

By Company

• Clinigen
• Sun Pharmaceutical
• Taj Pharmaceuticals
• Merro Pharmaceutical
• Luye Pharma
• Mingren Pharma

Segment by Type

• 400mg/Dose
• 500mg/Dose

Segment by Application

• Head and Neck Cancer Adjuvant Therapy
• Others

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Amifostine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Amifostine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Amifostine in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Amifostine Product Introduction
• 1.2 Global Amifostine Market Size Forecast
  • 1.2.1 Global Amifostine Sales Value (2020-2031)
  • 1.2.2 Global Amifostine Sales Volume (2020-2031)
  • 1.2.3 Global Amifostine Sales Price (2020-2031)
• 1.3 Amifostine Market Trends & Drivers
  • 1.3.1 Amifostine Industry Trends
  • 1.3.2 Amifostine Market Drivers & Opportunity
  • 1.3.3 Amifostine Market Challenges
  • 1.3.4 Amifostine Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Amifostine Players Revenue Ranking (2024)
• 2.2 Global Amifostine Revenue by Company (2020-2025)
• 2.3 Global Amifostine Players Sales Volume Ranking (2024)
• 2.4 Global Amifostine Sales Volume by Company Players (2020-2025)
• 2.5 Global Amifostine Average Price by Company (2020-2025)
• 2.6 Key Manufacturers Amifostine Manufacturing Base and Headquarters
• 2.7 Key Manufacturers Amifostine Product Offered
• 2.8 Key Manufacturers Time to Begin Mass Production of Amifostine
• 2.9 Amifostine Market Competitive Analysis
  • 2.9.1 Amifostine Market Concentration Rate (2020-2025)
  • 2.9.2 Global 5 and 10 Largest Manufacturers by Amifostine Revenue in 2024
  • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Amifostine as of 2024)
• 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 400mg/Dose
  • 3.1.2 500mg/Dose
• 3.2 Global Amifostine Sales Value by Type
  • 3.2.1 Global Amifostine Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Amifostine Sales Value, by Type (2020-2031)
  • 3.2.3 Global Amifostine Sales Value, by Type (%) (2020-2031)
• 3.3 Global Amifostine Sales Volume by Type
  • 3.3.1 Global Amifostine Sales Volume by Type (2020 VS 2024 VS 2031)
  • 3.3.2 Global Amifostine Sales Volume, by Type (2020-2031)
  • 3.3.3 Global Amifostine Sales Volume, by Type (%) (2020-2031)
• 3.4 Global Amifostine Average Price by Type (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Head and Neck Cancer Adjuvant Therapy
  • 4.1.2 Others
• 4.2 Global Amifostine Sales Value by Application
  • 4.2.1 Global Amifostine Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Amifostine Sales Value, by Application (2020-2031)
  • 4.2.3 Global Amifostine Sales Value, by Application (%) (2020-2031)
• 4.3 Global Amifostine Sales Volume by Application
  • 4.3.1 Global Amifostine Sales Volume by Application (2020 VS 2024 VS 2031)
  • 4.3.2 Global Amifostine Sales Volume, by Application (2020-2031)
  • 4.3.3 Global Amifostine Sales Volume, by Application (%) (2020-2031)
• 4.4 Global Amifostine Average Price by Application (2020-2031)

5 Segmentation by Region

• 5.1 Global Amifostine Sales Value by Region
  • 5.1.1 Global Amifostine Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Amifostine Sales Value by Region (2020-2025)
  • 5.1.3 Global Amifostine Sales Value by Region (2026-2031)
  • 5.1.4 Global Amifostine Sales Value by Region (%), (2020-2031)
• 5.2 Global Amifostine Sales Volume by Region
  • 5.2.1 Global Amifostine Sales Volume by Region: 2020 VS 2024 VS 2031
  • 5.2.2 Global Amifostine Sales Volume by Region (2020-2025)
  • 5.2.3 Global Amifostine Sales Volume by Region (2026-2031)
  • 5.2.4 Global Amifostine Sales Volume by Region (%), (2020-2031)
• 5.3 Global Amifostine Average Price by Region (2020-2031)
• 5.4 North America
  • 5.4.1 North America Amifostine Sales Value, 2020-2031
  • 5.4.2 North America Amifostine Sales Value by Country (%), 2024 VS 2031
• 5.5 Europe
  • 5.5.1 Europe Amifostine Sales Value, 2020-2031
  • 5.5.2 Europe Amifostine Sales Value by Country (%), 2024 VS 2031
• 5.6 Asia Pacific
  • 5.6.1 Asia Pacific Amifostine Sales Value, 2020-2031
  • 5.6.2 Asia Pacific Amifostine Sales Value by Region (%), 2024 VS 2031
• 5.7 South America
  • 5.7.1 South America Amifostine Sales Value, 2020-2031
  • 5.7.2 South America Amifostine Sales Value by Country (%), 2024 VS 2031
• 5.8 Middle East & Africa
  • 5.8.1 Middle East & Africa Amifostine Sales Value, 2020-2031
  • 5.8.2 Middle East & Africa Amifostine Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Amifostine Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Amifostine Sales Value and Sales Volume
  • 6.2.1 Key Countries/Regions Amifostine Sales Value, 2020-2031
  • 6.2.2 Key Countries/Regions Amifostine Sales Volume, 2020-2031
• 6.3 United States
  • 6.3.1 United States Amifostine Sales Value, 2020-2031
  • 6.3.2 United States Amifostine Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Amifostine Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Amifostine Sales Value, 2020-2031
  • 6.4.2 Europe Amifostine Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Amifostine Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Amifostine Sales Value, 2020-2031
  • 6.5.2 China Amifostine Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Amifostine Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Amifostine Sales Value, 2020-2031
  • 6.6.2 Japan Amifostine Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Amifostine Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Amifostine Sales Value, 2020-2031
  • 6.7.2 South Korea Amifostine Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Amifostine Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Amifostine Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Amifostine Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Amifostine Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Amifostine Sales Value, 2020-2031
  • 6.9.2 India Amifostine Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Amifostine Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 Clinigen
  • 7.1.1 Clinigen Company Information
  • 7.1.2 Clinigen Introduction and Business Overview
  • 7.1.3 Clinigen Amifostine Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.1.4 Clinigen Amifostine Product Offerings
  • 7.1.5 Clinigen Recent Development
• 7.2 Sun Pharmaceutical
  • 7.2.1 Sun Pharmaceutical Company Information
  • 7.2.2 Sun Pharmaceutical Introduction and Business Overview
  • 7.2.3 Sun Pharmaceutical Amifostine Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.2.4 Sun Pharmaceutical Amifostine Product Offerings
  • 7.2.5 Sun Pharmaceutical Recent Development
• 7.3 Taj Pharmaceuticals
  • 7.3.1 Taj Pharmaceuticals Company Information
  • 7.3.2 Taj Pharmaceuticals Introduction and Business Overview
  • 7.3.3 Taj Pharmaceuticals Amifostine Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.3.4 Taj Pharmaceuticals Amifostine Product Offerings
  • 7.3.5 Taj Pharmaceuticals Recent Development
• 7.4 Merro Pharmaceutical
  • 7.4.1 Merro Pharmaceutical Company Information
  • 7.4.2 Merro Pharmaceutical Introduction and Business Overview
  • 7.4.3 Merro Pharmaceutical Amifostine Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.4.4 Merro Pharmaceutical Amifostine Product Offerings
  • 7.4.5 Merro Pharmaceutical Recent Development
• 7.5 Luye Pharma
  • 7.5.1 Luye Pharma Company Information
  • 7.5.2 Luye Pharma Introduction and Business Overview
  • 7.5.3 Luye Pharma Amifostine Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.5.4 Luye Pharma Amifostine Product Offerings
  • 7.5.5 Luye Pharma Recent Development
• 7.6 Mingren Pharma
  • 7.6.1 Mingren Pharma Company Information
  • 7.6.2 Mingren Pharma Introduction and Business Overview
  • 7.6.3 Mingren Pharma Amifostine Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.6.4 Mingren Pharma Amifostine Product Offerings
  • 7.6.5 Mingren Pharma Recent Development

8 Industry Chain Analysis

• 8.1 Amifostine Industrial Chain
• 8.2 Amifostine Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Amifostine Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Amifostine Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer